However, the increased prevalency of p53 pathway mutations within relapsed neuroblastoma tumors (Carr-Wilkinson et al., 2010), suggests that HDACi acting via this mechanism may not be as effective as second line treatments. This evidence concerns the gene TP53 and neuroblastoma.